Marketing Authorization (MA) of Valsartan 40mg, 80mg, 160mg and 320mg film-coated Tablets are granted by UK MHRA

Sciecure has been devoting on the development, manufacturing, and sale for the new and generic drugs with the high quality for both the domestic and international markets. Some have been passed the inspections by CFDA. With the growing demanding, our company has focused to develop the overseas markets in the pharmaceutical field, a number of these products has been submitted in Europe and USA.

1. Marketing Authorization (MA) of Aripiprazole 5mg, 10mg, 15mg, and 30mg tablets are granted by UK MHRA on 30 September, 2016.

2. Marketing Authorization (MA) of Voriconazole 50mg and 200mg tablets are granted by UK MHRA on 7 October, 2016.

3. Marketing Authorization (MA) of Pregabalin 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg hard capsules are granted by UK MHRA on 20 January, 2017.

4. Marketing Authorization (MA) of Levetiracetam Sciecure 100mg/ml concentrate for solution for infusion is granted by UK MHRA on 15 February, 2017.

5. Marketing Authorization (MA) of Candesartan Cilexetil 2mg, 4mg, 8mg, 16mg, 32mg Tablets are granted by UK MHRA on 03 May, 2017.

6. Marketing Authorization (MA) of Valsartan 40mg, 80mg, 160mg and 320mg film-coated Tablets are granted by UK MHRA on 05 June, 2017.

These are the great achievements for our company, and we will continue to develop more high quality drugs to benefit the societies.